Can chronic lymphocytic leukemia (CLL) achieve remission?

Yes, CLL Can Achieve Remission

Yes, chronic lymphocytic leukemia (CLL) can achieve remission, including deep remissions with undetectable minimal residual disease (MRD), though CLL remains incurable and requires lifelong monitoring. The depth and duration of remission depend heavily on treatment type, genetic risk factors, and disease biology 1.

Understanding Remission in CLL

Modern targeted therapies have fundamentally changed what remission means in CLL:

Deep Remission with Targeted Agents

Time-limited combination therapies, particularly venetoclax-based regimens, can achieve undetectable MRD status in many patients, which correlates with prolonged progression-free survival 2. The 2024 ESMO guidelines emphasize that:

• Venetoclax plus obinutuzumab achieves high rates of undetectable MRD, particularly in patients with mutated IGHV status 2
• Ibrutinib plus venetoclax combinations produce durable remissions, even in high-risk patients with unmutated IGHV or TP53 aberrations 2
• Patients achieving bone marrow MRD-negative complete remission have superior progression-free and overall survival 3

Key Distinction: Remission vs. Cure

CLL is considered incurable despite achieving remission 1. This means:

• Even patients in deep remission with undetectable MRD can eventually relapse
• Lifelong monitoring is required for all patients 4
• The disease may remain dormant for years but typically returns

Remission Patterns by Treatment Type

With Chemoimmunotherapy (CIT)

Traditional FCR (fludarabine, cyclophosphamide, rituximab) therapy can produce:

• Complete remissions in fit, young patients with mutated IGHV
• Long remission durations (>3 years) in favorable-risk patients 1
• However, patients with TP53 mutations/del(17p) have poor outcomes with CIT 1

With BTK Inhibitors (Continuous Therapy)

Ibrutinib, acalabrutinib, and zanubrutinib typically produce:

• Partial remissions rather than complete remissions 3
• Disease control that requires continuous therapy to maintain
• Stopping therapy usually leads to disease progression 1

With Time-Limited Targeted Combinations

This represents the most promising approach for achieving durable remission:

• Venetoclax-obinutuzumab for 12 months achieves high uMRD rates 2
• Ibrutinib-venetoclax combinations produce deep remissions with fixed duration 2
• Patients can remain in remission for years after stopping therapy 1

Remission Duration and Relapse

Long-Lasting Remissions (>3 Years)

Patients achieving remission lasting >36 months can be re-exposed to the same treatment regimen 1. The 2021 ESMO guidelines specifically state that patients with long-lasting remissions may be retreated with their initial therapy 1.

Short Remissions (<3 Years)

If relapse occurs within 36 months, the therapeutic regimen should be changed 1. This applies regardless of whether first-line therapy was CIT or novel targeted agents 1.

Asymptomatic Relapse

A critical point: Many patients with relapsed but asymptomatic CLL can be followed without therapy for extended periods 1. Even stopping continuous BCR inhibitors or venetoclax doesn't necessarily require immediate alternative treatment if CLL is in remission 1.

Genetic Factors Affecting Remission

TP53 Mutations/del(17p)

These high-risk patients:

• Have shorter remissions with most therapies
• Should receive BTK inhibitors or venetoclax-based regimens first-line 1
• Show less efficacy even with venetoclax-obinutuzumab, though better than CIT 1

IGHV Mutation Status

• Mutated IGHV: Higher rates of undetectable MRD (41% vs 13%) and longer remissions 5
• Unmutated IGHV: Shorter remissions with time-limited therapy, may benefit from continuous treatment 2

Rare Spontaneous Remissions

Spontaneous remission of CLL is extremely rare but documented 6. A study identified 21 cases showing:

• 67% regressed to monoclonal B-lymphocytosis (MBL)
• 33% achieved normal phenotype
• Median CLL duration before remission: 13 years for MBL group vs 3 years for normal phenotype 6

One case report documented spontaneous regression after SARS-CoV-2 infection, suggesting possible immune-mediated mechanisms 7.

Clinical Implications

When to Treat Relapse

Treatment at relapse should only be started in symptomatic patients, not simply at disease reappearance 1. This is a common pitfall—asymptomatic progression on imaging or labs alone doesn't mandate immediate treatment.

Monitoring in Remission

• Blood counts and physical examination every 3-12 months 4
• Watch for autoimmune cytopenias
• Screen for secondary malignancies (2-7 fold increased risk) 4

MRD Testing Significance

More sensitive MRD testing (10^-6 by NGS) provides better prognostic discrimination than standard flow cytometry (10^-4) 5. Patients with undetectable MRD by NGS have superior progression-free survival, with median not reached versus 67 months for MRD-positive patients 5.